Tim Brandenburg

9PUBLICATIONS
23CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Sep 28, 2026
Clinical Outcomes of Pembrolizumab Combination Therapy in Heavily Pretreated PDTC and Anaplastic Thyroid Cancer.

|May 04, 2026
Anaplastic thyroid cancer: Cases, incidence, prevalence and survival in Germany.

|Apr 28, 2026
Outcome of first-line chemotherapy for anaplastic thyroid cancer-a multicenter registry analysis.

|Dec 23, 2025
Real-world efficacy and safety of selpercatinib in RET-mutant medullary thyroid cancer at a Tertiary Referral Center.

Yara Maria Machlah, Lynn Marlene Srasra, Sarah Theurer

|May 23, 2025
Comprehensive Assessment of Multikinase Inhibitor Therapy Outcomes in RAIR-(P)DTC and MTC at a Tertiary Referral Center.

Yara Maria Machlah, Tim Brandenburg, Philipp Muchalla

|Nov 15, 2023
Risk and Incidence of Endocrine Immune-Related Adverse Effects Under Checkpoint Inhibitor Mono- or Combination Therapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials.

Irfan Vardarli, Susanne Tan, Tim Brandenburg

Pageof 2

Frequent Collaborators

4 joint publications

Yara Maria Machlah

3 joint publications

Kerstin Lorenz

2 joint publications

Andreas Machens

2 joint publications

Dagmar Fuhrer